BCM
BRNS

BlueCrest Capital Management’s Barinthus Biotherapeutics BRNS Stock Holding History

BlueCrest Capital Management’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-542,673
Closed -$646K – 99
2024
Q3 		$646K Hold
542,673
– – 0.03% 64
2024
Q2 		$760K Hold
542,673
– – 0.04% 81
2024
Q1 		$1.29M Hold
542,673
– – 0.06% 146
2023
Q4 		$2M Hold
542,673
– – 0.08% 147
2023
Q3 		$1.68M Hold
542,673
– – 0.07% 151
2023
Q2 		$1.12M Hold
542,673
– – 0.04% 142
2023
Q1 		$1.22M Hold
542,673
– – 0.04% 142
2022
Q4 		$1.28M Hold
542,673
– – 0.03% 107
2022
Q3 		$1.74M Hold
542,673
– – 0.05% 119
2022
Q2 		$2.42M Hold
542,673
– – 0.09% 105
2022
Q1 		$2.82M Sell
542,673
-400
-0.1% -$3.23K 0.09% 125
2021
Q4 		$6.03M Buy
+543,073
New +$6.85M 0.19% 86

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

BlueCrest Capital Management's BRNS Position: Q4 2024 in Review

BlueCrest Capital Management sold out of Barinthus Biotherapeutics (BRNS) in Q4 2024, closing a stake of 542,673 shares — an estimated $646K sold.

BlueCrest Capital Management first reported a position in BRNS in Q4 2021 and held it in 12 quarters. The position peaked at $6.03M in Q4 2021. 16 funds tracked by Wall St. Rank hold BRNS as of Q4 2024.

  • BlueCrest Capital Management reported no remaining Barinthus Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • BlueCrest Capital Management sold 542,673 Barinthus Biotherapeutics shares in Q4 2024, an estimated $646K.
  • BlueCrest Capital Management first reported a position in Barinthus Biotherapeutics in Q4 2021 and held it in 12 quarters.
  • BlueCrest Capital Management's Barinthus Biotherapeutics position peaked at $6.03M in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q4 2024.

Based on BlueCrest Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.